Skip to content

Author

H. Yanaihara

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Recurrence score prediction formula based on immunohistochemistry and biopsy data to predict response to neoadjuvant chemotherapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer

Oncotype DX® is a validated 21-gene tool for assessing survival benefits of adjuvant chemotherapy for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer, but its use in core biopsy specimens is limited by costs, access issues, and available tissue volumes, highlight...

K. Sotome, Yuuki Mae, Takako Yanagisawa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.